<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682057</url>
  </required_header>
  <id_info>
    <org_study_id>RH-01</org_study_id>
    <nct_id>NCT01682057</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension</brief_title>
  <official_title>A Prospective, Non-Randomized, Open Label, Multi-Center Study to Evaluate the ROX Anastomotic Coupler System (ACS) in Patients With Severe Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ROX Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ROX Medical, Inc.</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the ROX Anastomotic
      Coupler System (ACS) in patients with severe hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in mean office SBP</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mean office SBP at six months as compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean office DBP</measure>
    <time_frame>Change in mean office DBP six months as compared to Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mean office DBP at six months as compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ROX ANASTOMOTIC COUPLER SYSTEM (ACS)</intervention_name>
    <description>The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ROX Anastomotic Coupler System (ACS)</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe hypertension must be made on the basis of current findings,
             medical history, and physical examination

        Exclusion Criteria:

          -  Any serious medical condition that may adversely affect the patient's safety, limit
             the subject's ability to participate in the study, comply with follow-up requirements
             or impact the scientific integrity of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 12, 2013</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Blood Pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Resistant Hypertension</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
